President Donald Trump’s choice to lead America’s Food and Drug Administration (FDA) is Dr. Marty Makary, a surgeon who gained international attention during thePresident Donald Trump’s choice to lead America’s Food and Drug Administration (FDA) is Dr. Marty Makary, a surgeon who gained international attention during the

WSJ: Trump's new FDA pick is a disaster

2026/05/04 02:29
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

President Donald Trump’s choice to lead America’s Food and Drug Administration (FDA) is Dr. Marty Makary, a surgeon who gained international attention during the COVID-19 pandemic for his opposition to vaccine mandates. On paper, Makary seems like a great choice for the job, but a conservative newspaper is reporting “soap opera”-level drama associated with his tenure.

“Has any Trump administration official caused more political headaches for the president than Marty Makary?” wrote Allysia Finley of The Wall Street Journal on Sunday. “His Food and Drug Administration has turned into a soap opera, with real lives hanging in the balance.”

To illustrate this point, Finley described how "in public interviews, [Makary] boasts about accelerating access to gene therapies and rare-disease drugs, even as he and his deputies block them." Describing Makary as “slicker than a pharmaceutical salesman,” the Journal reporter observed that “my sources say that patience with Dr. Makary is wearing thin among Republicans in Congress and White House officials."

Since taking office, Makary has rejected rare-disease and cancer drugs, a gene therapy for Huntington’s Disease and various other medicines that had demonstrably improved or even saved lives. He has also been accused of allowing conflicts of interest to override his detached clinical judgment.

“Members of Congress are also investigating whistleblower complaints of retaliation by agency leadership against FDA staff who have recommended approvals of drugs with which Dr. Makary and his left-hand man, Vinay Prasad, disagreed,” Finley reported. “Dr. Prasad is a Bernie Sanders acolyte whom the commissioner tapped to lead the FDA’s biologics and gene-therapy division.”

Finley also quoted a Republican, Sen. Ron Johnson of Wisconsin, as saying that “the stories are so outrageous. It just appears that they're looking for excuses to say no." Johnson also reported rumors that the FDA has kept a “blacklist” of companies that “make too much noise.”

Finely concluded, "It's time for Mr. Trump to pull the plug on the Makary show."

Although not mentioned in her editorial, the FDA is also under fire for seeming to pull back from its responsibilities to protect food. Under Makary’s tenure, the FDA announced it would no longer engage in routine food inspections, describing that job as superfluous and instead arguing federal inspectors should offload all of those responsibilities to local authorities.

"There's so much work to go around. And us duplicating their work just doesn't make sense," a former FDA official explained to CBS News at the time.

The FDA has also been criticized for incorrectly saying that COVID vaccines have caused child deaths, a policy that Dr. Celine Grounder of KFF Health News denounced for allegedly endangering the public.

“What is unfolding inside the FDA is not a narrow dispute over covid vaccines,” Grounder argued. “It is an attempt, according to critics and vaccine scientists, to rewrite the rules governing the entire U.S. vaccine system — how risks are weighed, how benefits are proved, and how quickly lifesaving shots reach the public.”

Grounder concluded, “Former agency leaders warn that if these changes take hold, the consequences could be lasting: fewer vaccines, slower updates, weakened public trust, and more preventable outbreaks.”

  • george conway
  • noam chomsky
  • civil war
  • Kayleigh mcenany
  • Melania trump
  • drudge report
  • paul krugman
  • Lindsey graham
  • Lincoln project
  • al franken bill maher
  • People of praise
  • Ivanka trump
  • eric trump
Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$2.339
$2.339$2.339
+0.21%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

XRP Ledger Upgrade Progress Puts $3.06 Resistance in Focus

XRP Ledger Upgrade Progress Puts $3.06 Resistance in Focus

The post XRP Ledger Upgrade Progress Puts $3.06 Resistance in Focus appeared on BitcoinEthereumNews.com. XRPL Hub upgrade enhances validator connectivity and reliability for institutions XRP price trends show cautious optimism with resistance near $3.06 and support at $2.98 Technical indicators signal mild momentum as RSI holds neutral and MACD shows gains Chief Technology Officer David Schwartz has shared a fresh update on the ongoing XRP Ledger (XRPL) upgrade.  In a tweet on X today, he said “It’s going awesome! Here’s the past week,” highlighting steady progress on the XRPL Hub. The Hub, first unveiled on August 26, is designed to enhance network performance and reliability for institutional users. Related: Could 2,000 XRP Today Be Worth $100K by 2026? While testing experienced minor setbacks, the upgrade promises a faster, more stable, and more reliable infrastructure, potentially transforming how banks and large financial institutions interact with the XRP network. What the XRPL Hub Brings to the Table The XRPL Hub functions as a powerful server enhancing validator connectivity and network reliability. Consequently, it reduces the risk of outages and improves transaction load times. This improvement is particularly significant for institutions that demand uninterrupted access to financial services.  Moreover, the upgrade is a personal initiative from Schwartz rather than a standard Ripple product, highlighting his confidence in XRPL’s potential. By independently boosting the ecosystem, Schwartz underscores a long-term commitment to benefiting the XRP community and strengthening the network’s institutional adoption. XRP Price Trends and Market Outlook XRP is currently trading at $3.02, reflecting a 1.3% increase in the past 24 hours. The price movement shows moderate upward momentum, with higher lows indicating sustained buying interest. Key support sits around $2.98, while immediate resistance appears just above $3.06.  If XRP breaks past this resistance, further upward movement is likely. However, a retracement could retest the $2.98 support level. Trading volume in the last 24 hours reached $4.81 billion,…
Share
BitcoinEthereumNews2025/09/18 01:19
Tether Q1 2026 Net Profit Tops $1B, Attestation Report Shows

Tether Q1 2026 Net Profit Tops $1B, Attestation Report Shows

Tether says its Q1 2026 net profit exceeded $1 billion, according to its attestation report. Here is the key takeaway and why it matters.
Share
CoinLive2026/05/04 03:58
FLOKI Price Prediction: Death Cross Formation Points to $0.000180 Target Within 14 Days

FLOKI Price Prediction: Death Cross Formation Points to $0.000180 Target Within 14 Days

FLOKI technical indicators converge on bearish breakdown as daily volume collapses to $1.7M. Critical support at $0.000180 faces imminent test with 25% downside
Share
BlockChain News2026/05/03 16:23

Starter Gold Rush: Win $2,500!

Starter Gold Rush: Win $2,500!Starter Gold Rush: Win $2,500!

Start your first trade & capture every Alpha move